US2016287903A1PendingUtilityA1
System and method for determining amount of radioactive material to administer to a patient
Est. expiryNov 21, 2026(~0.3 yrs left)· nominal 20-yr term from priority
A61B 6/032A61B 6/037A61N 2005/1089A61B 6/5217A61N 5/1031A61N 5/1039
43
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A computerized system and method are provided for determining an optimum amount of radioactivity to administer to a patient, comprising: assuming an activity retention limit; utilizing the activity retention limit to determine a dose rate for a phantom category; utilizing the dose rate for the phantom category to determine the dose rate for a second phantom category; and utilizing the dose rate for a second phantom category to find information regarding the second phantom category. In other embodiments, a computerized system and method are provided for determining an optimum amount of radioactivity to administer to a patient, comprising: obtaining at least one image relating to anatomy of a particular patient; obtaining multiple images regarding radioactivity distribution over time in the particular patient; combining the radioactivity images with the anatomy images; running a Monte Carlo simulation to obtain dose image information; and using the dose image information to obtain BED and/or EUD information.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A computerized method for determining an optimum amount of radioactivity to administer to a patient, comprising:
assuming an activity retention limit; utilizing the activity retention limit to determine a dose rate for a phantom category; utilizing the dose rate for the phantom category to determine the dose rate for a second phantom category; and utilizing the dose rate for a second phantom category to find information regarding the second phantom category.
2 . The method of claim 1 , wherein the information is the activity retention limit for the second phantom category.
3 . The method of claim 1 , further comprising:
obtaining the mean absorbed dose by integrating the dose rate over time; using the mean absorbed dose to determine an optimum amount of radioactivity to administer to the patient.
4 . The method of claim 1 , wherein a dose rate resulting from short range particulate emissions is distinguished from a dose rate resulting from longer range emissions.
5 . The method of claim 4 , wherein the short range particulate emissions are electrons.
6 . The method of claim 4 , wherein the longer range emissions are photons.
7 . The method of claim 1 , wherein utilizing the activity retention limit to determine the dose rate for the phantom category further comprises calculating how the dose rate is related to the activity retention limit in a particular point in time.
8 . The method of claim 1 , wherein utilizing the activity retention limit to determine the dose rate for the phantom category further comprises using the following formula:
DR P ( t )= A LU ( t )· S LU←LU P +A RB ( t )· S LU←RB P (1),
with:
A
LU
(
t
)
=
A
T
·
F
T
-
π
LU
·
T
-
λ
LU
·
T
,
(
2
)
A
RB
(
t
)
=
A
T
·
(
1
-
F
T
)
-
λ
RB
·
T
-
λ
RB
·
T
,
(
3
)
S
LU
←
RB
P
=
S
LU
←
TB
P
·
M
TB
P
M
TB
P
-
M
LU
P
-
S
LU
←
LU
P
·
M
LU
P
M
TB
P
-
M
LU
P
,
(
4
)
A LU (t) lung activity at time t,|
S LU←LU P lung to lung 131 I S-factor for reference phantom, P,
A RB (t) remainder body activity (total-body-lung) at time, t,
S LU←RB P remainder body to hung 131 I S-factor for reference phantom, P,
A T whole-body activity at time, T,
F T fraction of A T that is in the lungs at time, T,
λ LU effective clearance rate from lungs (=ln(2)/T E ; with T E =effective half-life),
λRB effective clearance rate from remainder body (=ln(2)/T RB , with T RB =effective half-life in remainder body),
S LU←TB P total-body to lung 131 I S-factor for reference phantom. P,
M RB P total-body mass of reference phantom. P,
M LU P lung mass of reference phantom. P.
9 . The method of claim 3 , wherein obtaining the mean absorbed dose by integrating the dose rate over time further comprises utilizing the following formula:
DLU= Ã LU ·S LU←LU P +Ã RB ·S LU←RB P (9)
with
A
~
LU
=
A
DRC
P
·
F
48
·
l
n
(
2
)
T
E
T
ln
(
2
)
·
T
E
,
(
10
)
A
~
RB
=
A
DRC
P
·
(
1
-
F
48
)
·
l
n
(
2
)
T
RB
·
T
ln
(
2
)
·
T
RB
.
(
11
)
10 . A computerized system for determining an optimum amount of radioactivity to administer to a patient, comprising:
a server coupled to a network; a user terminal coupled to the network; an application coupled to the server and/or the user terminal, wherein the application is configured for:
assuming an activity retention limit;
utilizing the activity retention limit to determine a dose rate for a phantom category;
utilizing the dose rate for the phantom category to determine the dose rate for a second phantom category; and
utilizing the dose rate for a second phantom category to find information regarding the second phantom category.
11 . The system of claim 10 , wherein the information is the activity retention limit for the second phantom category.
12 . The system of claim 10 , wherein the application is further configured for: obtaining the mean absorbed dose by integrating the dose rate over time; using the mean absorbed dose to determine an optimum amount of radioactivity to administer to the patient.
13 . The system of claim 10 , wherein a dose rate resulting from short range particulate emissions is distinguished from a dose rate resulting from longer range emissions.
14 . The system of claim 13 , wherein the short range particulate emissions are electrons.
15 . The system of claim 13 , wherein the longer range emissions are photons.
16 . The system of claim 10 , wherein utilizing the activity retention limit to determine the dose rate for the phantom category further comprises calculating how the dose rate is related to the activity retention limit in a particular point in time.
17 . The system of claim 10 , wherein utilizing the activity retention limit to determine the dose rate for the phantom category further comprises using the following formula:
DR P ( t )= A LU ( t ) ·S LU←LU P +A RB ( t )· S LU←RB P (1),
with:
A
LU
(
t
)
=
A
T
·
F
T
-
π
RB
·
T
-
λ
LU
·
T
,
(
2
)
A
RB
(
t
)
=
A
T
·
(
1
-
F
T
)
-
λ
RB
·
T
-
λ
RB
·
T
,
(
3
)
S
LU
←
RB
P
=
S
LU
←
TB
P
·
M
TB
P
M
TB
P
-
M
LU
P
-
S
LU
←
LU
P
·
M
LU
P
M
TB
P
-
M
LU
P
,
(
4
)
A LU (t) lung activity at time t,|
S LU←LU P lung to lung 131 I S-factor for reference phantom, P,
A RB (t) remainder body activity (total-body-lung) at time, t,
S LU←RB P remainder body to hung 131 I S-factor for reference phantom, P,
A T whole-body activity at time, T,
F T fraction of A T that is in the lungs at time, T,
λ LU effective clearance rate from lungs (=ln(2)/T E ; with T E =effective half-life),
λRB effective clearance rate from remainder body (=ln(2)/T RB , with T RB =effective half-life in remainder body),
S LU←RB P total-body to lung 131 I S-factor for reference phantom. P,
M RB P total-body mass of reference phantom. P,
M LU P lung mass of reference phantom. P.
18 . The method of claim 12 , wherein obtaining the mean absorbed dose by integrating the dose rate over time further comprises utilizing the following formula:
DLU= Ã LU ·S LU←LU P +Ã RB ·S LU←RB P (9)
with
A
~
LU
=
A
DRC
P
·
F
48
·
l
n
(
2
)
T
E
T
ln
(
2
)
·
T
E
,
(
10
)
A
~
RB
=
A
DRC
P
·
(
1
-
F
48
)
·
l
n
(
2
)
T
RB
·
T
ln
(
2
)
·
T
RB
.
(
11
)Join the waitlist — get patent alerts
Track US2016287903A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.